Spasmex treatment of patients with hyperactive urinary bladder


Cite item

Full Text

Abstract

Overactive urinary bladder (HAUB) is encountered in 16-20% patients with various voiding disorders. Etiologically, detrusor hyperactivity can be neurogenic and idiopathic. We studied efficacy of the antimuscarine drug spasmex in patients with imperative voiding disorders and compared its efficacy and tolerance with those of driptan and detrusitol. 193 female patients with imperative voiding disorders were examined. Spasmex given in a dose of 5 mg 3 times a day for 12 weeks produced a good effect in 56 patients: increased the effective capacity of the urinary bladder, reduced the number of voidings and episodes of incontinence for a day. A 3-month course of spasmex proved highly effective as shown by the patients' subjective response and positive changes in objective evidence. Being equally effective with detrusitol and driptan, spasmex is much superior to oxibutynin in safety.

About the authors

D Yu Pushkar

О В Schaveleva

References

  1. Davila G. W., Neimark M. The overactive bladder: prevalence and effects on quality of life. Clin. Obstet. Gynecol. 2002; 45 (1): 173-181.
  2. DuBcau С. Е., Levy В., Mangione С. М. et al. The impact of urge incontinence on quality of life: importance of patients' perspective and explanatory style. J. Am. Geriatr. Soc. 1998; 46: 683-692.
  3. Hampel C., Weinhold D., Benken N., Eggersmann C. Prevalence and natural history of famale incontinence. Eur. Urol. 1997; 32 (suppl. 2): 3-12.
  4. Sullivan J., Abrams P. Overactive detrusor. Curr. Opin. Urol. 1999; 9 (4): 291-296.
  5. Abrams P., Kelleher С. J., Kerr L. A., Rogers R. G. Overactive bladder significantly affects quality of life. Am. J. Manag. Care 2000; 6 (11, suppl.): S580-S590.
  6. Blaivas J. G. Defining words: overactive bladder. Neurourol. and Urodynam. 1999; 18: 417-418.
  7. Andersson К. Е. Treatment of overactive bladder: other drug mechanisms. Urology 2000; 55 (5A, suppl.): 51-57; diuscus, 59,
  8. Joseph P. A., de Seze M. Genital and sphincter disorders. Rev. Neurol. (Paris) 2001; 157 (8-9, pt 2); 1051-1059.
  9. Milsom I., Abrams P., Cardozo L. et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br. J. Urol. Int. 2001; 87 (9): 760-766.
  10. Abrams P., Cardozo L., Fall M. et al. The standardization of terminology of lower urinary tract function: Report from the Standardization Subcommittee of ICS. Neurourol. and Urodynam. 2002; 21: 167-178.
  11. Шварц Г. Я., Кривобородов Г. Г., Шварц П. Г., Мазо Е. Б. Фармакотерапия урологических нарушений при рассеянном склерозе. Рус. мед. журн. 2000; 8 (5).
  12. Andersson К. Е. The concept of uroselectivity. Eur. Urol. 1998; 33 (suppl. 2): 7-12.
  13. Fusgen L., Hauri D. Trospium chloride: an effective option for medical treatment of bladder overactivity. Int. J. Clin. Pharmacol. Ther. 2000; 38: 223-234.
  14. Hofner K., Oelke M., Machtens S. Trospium chloride - an effective drug in the treatment of overactive bladder and detrusor hyperreflexia. Wld J. Urol. 2001; 19: 336-343.
  15. Tapp A. J. S., Cardozo L. D., Versi E. et al. The treatment of detrusor instability in post-menopausal women with oxibutynin chloride: a double blind placebo controlled study. Br. J. Obstet. Gynaecol. 1990; 97: 521-526.
  16. Donellan C. A., Fook L. et al. Oxibutynin and cognitive function. Br. Med. J. 1997; 315: 1363-1364.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2003 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies